Neoadjuvant and conversion treatment of patients with colorectal liver metastasis: the potential role of bevacizumab and other antiangiogenic agents

More than 50 % of patients with colorectal cancer develop liver metastases. Surgical resection is the only available treatment that improves survival in patients with colorectal liver metastases (CRLM). New antiangiogenic targeted therapies, such as bevacizumab, aflibercept, and regorafenib, in comb...

Descripción completa

Detalles Bibliográficos
Autores principales: García-Alfonso, Pilar, Ferrer, Ana, Gil, Silvia, Dueñas, Rosario, Pérez, María Teresa, Molina, Raquel, Capdevila, Jaume, Safont, María José, Castañón, Carmen, Cano, Juana María, Lara, Ricardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4668275/
https://www.ncbi.nlm.nih.gov/pubmed/25752908
http://dx.doi.org/10.1007/s11523-015-0362-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4668275/
https://www.ncbi.nlm.nih.gov/pubmed/25752908
http://dx.doi.org/10.1007/s11523-015-0362-0

Ejemplares similares